Company
Cytokinetics
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
2
Originals and new uses
Phase 3 trials
13
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionPivotal-lookingRecruiting
CytokineticsIndustry
NCT06736574 · 1,800 participants (planned) · Start Dec 19, 2024 · Primary completion Sep 2027
Drug: Omecamtiv Mecarbil (OM); Placebo · For: Heart Failure; Heart Failure With Reduced Ejection Fraction
Sites: Alexander City, Alabama; Birmingham, Alabama; Tucson, Arizona · 215 sites in all
Marketed drugs (1)
Newest FDA action first.
- Myqorzo Aficamten · 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.